Literature DB >> 28611010

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.

Deepa Rangachari1, Xiuning Le1, Meghan Shea1, Mark S Huberman1, Paul A VanderLaan2, Susumu S Kobayashi1, Daniel B Costa3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28611010      PMCID： PMC5659921          DOI： 10.1016/j.jtho.2017.06.002

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.

Authors:  Justin F Gainor; Daniel S W Tan; Tomasso De Pas; Benjamin J Solomon; Aziah Ahmad; Chiara Lazzari; Filippo de Marinis; Gianluca Spitaleri; Katherine Schultz; Luc Friboulet; Beow Y Yeap; Jeffrey A Engelman; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

2.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Authors:  Daniel B Costa; Alice T Shaw; Sai-Hong I Ou; Benjamin J Solomon; Gregory J Riely; Myung-Ju Ahn; Caicun Zhou; S Martin Shreeve; Paulina Selaru; Anna Polli; Patrick Schnell; Keith D Wilner; Robin Wiltshire; D Ross Camidge; Lucio Crinò
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

4.  Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

5.  Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Authors:  Alice T Shaw; Leena Gandhi; Shirish Gadgeel; Gregory J Riely; Jeremy Cetnar; Howard West; D Ross Camidge; Mark A Socinski; Alberto Chiappori; Tarek Mekhail; Bo H Chao; Hossein Borghaei; Kathryn A Gold; Ali Zeaiter; Walter Bordogna; Bogdana Balas; Oscar Puig; Volkmar Henschel; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2015-12-19       Impact factor: 41.316
  5 in total
  8 in total

1.  TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer.

Authors:  D B Costa
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

2.  From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.

Authors:  Deepa Rangachari; Daniel B Costa
Journal:  J Clin Oncol       Date:  2019-06-02       Impact factor: 44.544

3.  Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.

Authors:  Xiuning Le; Deepa Rangachari; Daniel B Costa
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

4.  Long-term complete response in a patient with postoperative recurrent ALK-rearranged lung adenocarcinoma treated with crizotinib: A case report.

Authors:  Takayuki Kosaka; Toshiki Yajima; Ei Yamaki; Seshiru Nakazawa; Kenji Tomizawa; Ryoichi Onozato; Ayako Yamazaki; Junko Hirato; Yasushi Yatabe; Kimihiro Shimizu; Akira Mogi; Ken Shirabe
Journal:  Mol Clin Oncol       Date:  2019-07-03

5.  ALK‑positive locally advanced lung cancer in a patient who achieved long‑term complete response with crizotinib: A case report.

Authors:  Levent Emirzeoglu; Ozgur Olmez
Journal:  Exp Ther Med       Date:  2022-09-02       Impact factor: 2.751

6.  Tumor biomarker testing in non-small-cell lung cancer: A decade of change.

Authors:  Paul A VanderLaan; Deepa Rangachari; Adnan Majid; Mihir S Parikh; Sidharta P Gangadharan; Michael S Kent; Danielle C McDonald; Mark S Huberman; Susumu S Kobayashi; Daniel B Costa
Journal:  Lung Cancer       Date:  2018-01-04       Impact factor: 5.705

7.  Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.

Authors:  Jose M Pacheco; Dexiang Gao; Derek Smith; Thomas Purcell; Mark Hancock; Paul Bunn; Tyler Robin; Arthur Liu; Sana Karam; Laurie Gaspar; Brian Kavanagh; Chad Rusthoven; Dara Aisner; Robert Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2018-12-30       Impact factor: 15.609

8.  Characteristics of central nervous system progression in non-small cell lung cancer treated with crizotinib or alectinib.

Authors:  Hiroaki Sakamoto; Noriko Yanagitani; Ryo Manabe; Ryosuke Tsugitomi; Shinsuke Ogusu; Takehiro Tozuka; Hiroshi Yoshida; Yoshiaki Amino; Ryo Ariyasu; Ken Uchibori; Satoru Kitazono; Sadatomo Tasaka; Makoto Nishio
Journal:  Cancer Rep (Hoboken)       Date:  2021-05-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.